Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of lurbinectedin + irinotecan in advanced desmoplastic small round cell tumor
2024-519261-21-00Phase 2Authorised
- Sponsor
- Italian Sarcoma Group
- Start
- Nov 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of lurbinectedin and irinotecan in desmoplastic small round cell tumor (DSRCT), sponsored by Italian Sarcoma Group. Primary endpoint: Overall tumour Response Rate. Planned start Nov 2025; status: authorised.
02
Drugs
lurbinectedinirinotecan
03
Conditions
desmoplastic small round cell tumor (DSRCT)
Beyond the preview
Go deeper on 2024-519261-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519261-21-00.